Navigation Links
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients

45 246 -45% VLDL-C 18 10 -44% 33 24 -26% 30 20 -33% Non-HDL 669 328 -51% 230 123 -46% 475 266 -44% HDL-C 27 35 32% 29 28 -2% 27 31 15% ApoA-1 86 92 7% 109 109 0% 89 90 2% TC 695 363 -48% 258 151 -41% 502 297 -41% TG 90 49 -45% 163 118 -28% 151 99 -34% Lp(a) 104 36 -65% 140 128 -9% 108 54 -50%

ISIS 301012 was well tolerated and there were no serious adverse events in the study. A single patient had a transient increase in liver transaminase (ALT) that exceeded three times the upper limit of normal (3xULN), which the investigator attributed to alcohol as documented by patient's admission.

Jeff Jonas, M.D., Executive Vice President, Isis Pharmaceuticals, commented, "We are pleased to have successfully completed this initial evaluation of ISIS 301012 in the extreme disease setting of homozygous FH and in combination with the high doses of other lipid-lowering drugs typically prescribed to these patients. We are preparing to initiate our registration studies for FH shortly, and we look forward to presenting more FH data later in the year."

More about Phase 2 Trials for ISIS 301012

Isis has presented results of two double-blind, placebo-controlled Phase 2 dosing studies in patients with routine high cholesterol (polygenic hypercholesterolemia): a monotherapy study and a five-week coadministration with statins study. Ongoing studies include an extended three-month 200 mg/week treatment cohort in the statin coadministration study in polygenic hypercholesterolemia, and a dose-escalation study in patients with heterozygous FH. Data for each of these studies will be reported later in the year. For future studies, including the registration studies for FH and the long-term coadministration study planned for patients with routine
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:4/16/2015)... Mass. , April 16, 2015  Hologic, ... important cervical cancer screening study i published ... a peer-reviewed journal of the American Cancer Society. ... Diagnostics and the University of Pittsburgh Medical Center, supports current ... which recommend that women 30-65 years of age ...
(Date:4/16/2015)... April 16, 2015  Amgen (NASDAQ: AMGN ) ... financial results on Tuesday, April 21, 2015, after the ... be followed by a conference call with the investment ... from Amgen will be Robert A. Bradway , ... Amgen,s senior management team. Live audio of ...
(Date:4/16/2015)... 2015 Today, Kenneth C. Frazier , chairman ... was elected chairman of the Board of the Pharmaceutical Research ... president and CEO John J. Castellani announced that ... New Officers Elected to PhRMA Board Frazier ... C. Read , chairman and CEO of Pfizer, Inc. Also ...
Breaking Medicine Technology:Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5
... today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam orally disintegrating tablets. Distribution of the product will commence immediately.   , ... ... ... ...
... Inc. (Nasdaq: MITI ) announced today the closing of its previously announced underwritten public offering. Prior to closing, the ... sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 ... ... , , ...
Cached Medicine Technology:Actavis Receives Approval of Alprazolam ODT in the U.S. 2Actavis Receives Approval of Alprazolam ODT in the U.S. 3Micromet Closes $80.5 Million Public Offering of Common Stock 2Micromet Closes $80.5 Million Public Offering of Common Stock 3Micromet Closes $80.5 Million Public Offering of Common Stock 4
(Date:4/17/2015)... (PRWEB) April 17, 2015 At the ... EcoLuxe Lounge and the “Salute to the Oscars” in ... Beverly Hilton Hotel, overlooking the impressive Los Angeles skyline. ... organized by Debbie Durkin, LA’s leading producer of sustainable ... many of the world’s premier providers of eco-friendly and ...
(Date:4/17/2015)... 17, 2015 Baptist Health and The ... a partnership agreement designed to transform oncology care in ... have agreed to create a joint cancer program to ... translational research. Baptist MD Anderson Cancer Center is anticipated ... single destination for highly coordinated, multidisciplinary cancer care for ...
(Date:4/17/2015)... The American College of Traditional Chinese Medicine (ACTCM) is ... April 29. The event will be held from 11 a.m. to ... St. in San Francisco, CA. , The agenda for the day ... DeHaro campus (room F), 11:10 a.m. – Introduction and welcome ... lunch with current students, faculty and staff, 1 p.m. – Observe ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog post ... insurance quotes . , The online environment can ... cars. Drivers should always compare multiple car insurance policies ... is a competitive one, which means that customers can ... It is now possible to compare online car insurance ...
(Date:4/17/2015)... released a new blog post explaining the dangers of sleeping ... rates . , Falling asleep at the wheel can ... impact on auto insurance prices. The premiums will go up ... newly released blog post talks more about drowsiness at the ... is now possible to find low cost car insurance plans ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:American College of Traditional Chinese Medicine Hosts Open House 2Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2
... help avoid treatment toxicity, research shows , WEDNESDAY, Sept. ... researchers may have found a better way for them ... , A regimen using antibodies instead of high-dose ... to Dr. Persis J. Amrolia, a doctor in the ...
... , ROCHESTER, N.Y., Sept. 2 "Everyone ... flu virus. Let me tell you about my personal encounter ... article on Dr. Hanan Polansky,s book, where he describes his ... After I read the article, I started taking Gene-Eden, a ...
... Agreement to Sell MDS Analytical Technologies to Danaher, ... Shareholders;, Announces Intent to Sell MDS Pharma Services, ... MDS; NYSE: MDZ ), a leading provider of products ... it has entered into an agreement to sell its MDS Analytical ...
... , , ... (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, ... and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both ... for calcitriol softgel capsules and oral liquid were $70 million (IMS ...
... , THE WOODLANDS, Texas, Sept. 2 ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough ... Sands, M.D., Ph.D. , Lexicon,s president and chief executive officer, ... Four Seasons Hotel in Boston, Massachusetts on Wednesday, September 9, 2009 ...
... ... bill compliance auditing, today announced their partnership with Pat Palmer, President and Founder of ... of whom are pioneers in the field of medical bill advocacy. , ... Boca Raton, FL (PRWEB) September ...
Cached Medicine News:Health News:New Technique Offers Hope for Kids With Immune Deficiency 2Health News:How to Protect Against the Swine Flu Virus: 'My Personal Experience with Gene-Eden(TM), a Broad Range Antiviral Supplement' 2Health News:MDS Announces Strategic Repositioning 2Health News:MDS Announces Strategic Repositioning 3Health News:MDS Announces Strategic Repositioning 4Health News:MDS Announces Strategic Repositioning 5Health News:MDS Announces Strategic Repositioning 6Health News:MDS Announces Strategic Repositioning 7Health News:MDS Announces Strategic Repositioning 8Health News:MDS Announces Strategic Repositioning 9Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 2Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 3Health News:Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:TrueFACS Announces the Addition of Nora Johnson and Pat Palmer of Medical Billing Advocates of America 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: